AstraZeneca Plc buys China unit of FibroGen Inc for $160 million
HQ Team February 21, 2025: FibroGen Inc., a US-based pharmaceutical company, will sell its China subsidiary to AstraZeneca Plc. for $160 million, allowing.
Drugs
Health
Pharma
Drugs
Health
Medical
WHO director-general rebuts US criticism, plans to cut budget
Tedros Adhanom Ghebreyesus, the Director-General of the World Health Organization, has given a four-point rebuttal to the US government’s accusations against the global.
Drugs
Health
Medical
China’s YolTech starts gene editing trial for treating a blood disorder
China’s YolTech Therapeutics, a biotechnology startup, has started its clinical trial of an investigational therapy for treating transfusion-dependent beta-thalassemia (TDT), a severe genetic.
Climate
Health
Medical
US to pull out from Paris Agreement that limits global warming
The US, the world’s second-largest greenhouse gas emitter in the world, will withdraw from a global pact to limit global warming.
Health
Medical
Pharma
US to withdraw from WHO after an executive order from Donald Trump
The US, the World Health Organization’s top donor, has decided to withdraw from the global health body, accusing it of “mishandling” the Covid-19.
Drugs
Health
Pharma
Vertex, China’s Zai to develop, commercialise kidney disease drug
US-based Vertex Pharmaceutical Inc. has signed a licensing pact with China’s Zai Lab Ltd. to develop and commercialise the Boston-headquartered company’s medicine, which.
Drugs
Health
Medical
China approves Merck’s human papillomavirus jab for use in males
China has approved Merck & Co.’s human papillomavirus vaccine for males between nine and 26 years amid a fall in sales for the.
Health
Medical
Pharma
China to make humanoid robots, brain-computer interfaces for elderly
China will develop humanoid robots for elderly care and support scientific and technological projects related to senior citizens, according to a state-run news.
Drugs
Health
Medical
Respiratory infections in China have no ‘unusual outbreak patterns’
A rise in cases of respiratory infections in China is within the expected range during this time of the year, and the World.
Drugs
Medical
Pharma
WuXi Biologics sells global rights to cancer antibody to Candid for $925m
China’s WuXi Biologics, a clinical research organization, has granted global rights to US-based Candid Therapeutics to use the company’s synthetic antibody to fight.